Olumiant

Monotherapy or in combination w/ MTX for moderate to severe active RA in adult patients who have responded inadequately to or who are intolerant to ≥1 DMARDs; active juvenile idiopathic arthritis in patients ≥2 yr who have had inadequate response or intolerance to ≥1 prior conventional synthetic or biologic DMARDs. Moderate to severe atopic dermatitis in adult patients whose disease is inadequately controlled w/ topical prescription therapies or when those therapies are not advisable; in patients ≥2 yr whose disease is inadequately controlled w/ conventional topical & systemic prescription therapies or when those therapies are not advisable. Severe alopecia areata in adult patients.

RA, atopic dermatitis & alopecia areata Adult 4 mg once daily, may be tapered to 2 mg once daily if sustained control of disease activity is achieved. Patient at higher risk of VTE, major adverse CV events & malignancy, ≥65 yr & w/ history of chronic or recurrent infections 2 mg once daily. May consider 4 mg once daily for those who do not achieve adequate control of disease activity w/ 2 mg once daily dose. Atopic dermatitits Childn ≥2 yr weighing ≥30 kg 4 mg once daily, 10 kg to <30 kg 2 mg once daily. Juvenile idiopathic arthritis Patient 2 to <18 yr weighing ≥30 kg 4 mg once daily, 10 kg to < 30 kg 2 mg once daily. Concomitant use w/ strong organic anion transporter 3 inhibitors (eg, probenecid) or w/ CrCl 30-60 mL/min Adult 2 mg. Childn Reduce dose by ½, weighing <30 kg Max: 1 mg once daily.

May be taken with or without food: May disperse tab in water for paed patients who are unable to swallow whole tab.

Hypersensitivity. Pregnancy.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

L04AF02 - baricitinib ; Belongs to the class of Janus-associated kinase (JAK) inhibitors. Used as immunosuppressants.

POM